Altogether, our results indicate that BC-N102 exhibited its therapeutic effect via suppression of PR and AR signaling while mediating the activation of MR signaling irrespective of the presence or absence of the receptor's ligand in the breast cancer cell line. This evidence concerns the gene AR and breast carcinoma.